Related Experiment Video

Updated: May 15, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Cabozantinib as a novel therapy for renal cell carcinoma

Ulka Vaishampayan1

  • 1Wayne State University, Detroit, Michigan, MI 48201, USA. vaishamu@karmanos.org

Current Oncology Reports
|January 8, 2013
PubMed

Insights

Cabozantinib shows promise in advanced kidney cancer, with significant response rates and improved progression-free survival. This targeted therapy also demonstrated notable benefits in bone metastases, offering new hope for patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cabozantinib (XL184) is a novel multi-targeted tyrosine kinase inhibitor.
  • Preclinical studies indicated activity against VEGF, KIT, and MET, relevant in various solid tumors including renal cancer.

Purpose of the Study:

  • To evaluate the efficacy and safety of cabozantinib in patients with advanced kidney cancer.
  • To explore the potential role of MET overexpression in patient selection for cabozantinib therapy.

Main Methods:

  • A Phase II clinical trial was conducted to assess cabozantinib's activity.
  • Objective response rate, disease control rate, and progression-free survival were key efficacy endpoints.

Main Results:

  • Cabozantinib demonstrated a 28% objective response rate and 62% disease control rate in renal cancer patients.
  • Median progression-free survival was 14.7 months, with notable responses in bone metastases.
  • Fatigue and diarrhea were the most common adverse events.

Conclusions:

  • Cabozantinib is a promising agent for advanced kidney cancer, particularly in managing bone metastases.
  • Further randomized trials comparing cabozantinib to standard VEGF inhibitors are warranted.
  • Identifying patients with MET overexpression may optimize treatment selection for this targeted therapy.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...